Atossa nears regulatory resolution for cancer Dx; German firm found liable in breast implant scandal;

@FierceMedDev: TriVascular lands $40M round for aortic stent grafts. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's latest earnings report comes out on Nov. 19. | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Brain tumors succumb to drugs delivered via bone scaffold. More | Follow @MichaelGFierce

> A court recently found the German safety standards firm TUV Rheinland liable in a global scandal over substandard breast implants made by the now-defunct French firm PIP. Story

> Atossa Genetics ($ATOS) said it had a fruitful pre-510(k) submission meeting with the FDA regarding its ForeCYTE Breast Pump and patient kit, potentially overcoming a warning letter that chided the company for marketing the now-recalled cancer diagnostic device without agency clearance. Item

> Corgenix has sealed a collaborative diagnostic test development deal with Zalgen Labs. Item

> A South Carolina startup envisions using magnets to lock and unlock a knee replacement system to help patients have more mobility. Story

> FBC Device gained a CE mark for its new spinal fusion plant and will launch the device in Europe and Canada. Item

Biotech News

@FierceBiotech: Tufts: Big Pharma bets its future on a swelling pipeline of biologic. Article | Follow @FierceBiotech

@JohnCFierce: AbbVie scores SVRs of 95% and 98% for GT1a and GT1b groups in first PhIII hep C study. More | Follow @JohnCFierce

@DamianFierce: FierceBiotech, coming soon to an Android near you. (Get your iPhone/iPad version in the iTunes store.) Download | Follow @DamianFierce

@EmilyMFierce: Federal government to transfer laboratory chimps to sanctuaries. Story | Follow @EmilyMFierce

> Big Pharma venture teams back Aileron's shift to early-stage R&D. Article

> Pfizer joins Roche, GSK in $32M round for Mission Therapeutics. More

> In another big cancer setback, Sanofi shutters fedratinib program. News

Pharma News

@FiercePharma: The weekend's best-read special report: Top Pharma Companies by 2012 Revenues. Read | Follow @FiercePharma

@EricPFierce: Pfizer gives BlackBerry the raspberry. Piece | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from #biotech products. Report | Follow @CarlyHFierce

> GlaxoSmithKline CEO: Big Pharma has to be willing to concede in India. News

> Princeton weighs emergency vaccine campaign with Novartis' Bexsero shot. More

> Takeda's new outsider CFO charged with $1B cost-cutting plan. Article

CRO News

> Post-merger PRA makes another buy, grabbing CRI Lifetree. More

> WuXi boosts outlook as Chinese CRO market swells. Story

> Icon rolls out data visualization tech for adaptive trials. News

> Quintiles expands trial monitoring to slash study costs. Article

> Report: Medpace up for $1.2B sale as CRO M&A heats up. Report

> Catalent cuts ribbon on Chinese trial-supply facility. Item

Biotech IT News

> Falling cost of next-gen sequencing to drive informatics boom. News

> Pfizer takes steps to protect itself from BlackBerry's woes. More

> Validic raises cash to turn mHealth app output into data hose. Piece

> Pfizer finally takes control of Twitter account. Item

> EMA warns of possible delay to final trial data transparency policy. Article

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.